CK-7 negative primary lung adenocarcinoma

Dimitri Tchienga; Noelani-Mei Ascio; Abid Qureshi; Sultana Razia; Genato Romulo; Armand Asarian; Philip Xiao; Brice Nouthe; Dominique Belinga

doi:10.1093/jscr/rjad316

CK-7 negative primary lung adenocarcinoma

J Surg Case Rep. 2023 Jun 15;2023(6):rjad316. doi: 10.1093/jscr/rjad316. eCollection 2023 Jun.

Authors

Dimitri Tchienga¹, Noelani-Mei Ascio¹, Abid Qureshi², Sultana Razia², Genato Romulo², Armand Asarian², Philip Xiao³, Brice Nouthe⁴, Dominique Belinga⁵

Affiliations

¹ Department of Surgery, St George's University School of Medicine, True Blue, Grenada, WI, USA.
² Department of Surgery, The Brooklyn Hospital Center, Icahn School of Medicine at Mount Sinai, Brooklyn, NY, USA.
³ Department of Pathology, The Brooklyn Hospital Center, Icahn School of Medicine at Mount Sinai, Brooklyn, NY, USA.
⁴ Fraser Health Authority/Department of Medicine, University of British Columbia, Vancouver, Canada.
⁵ China Medical University, Shenyang, Liaoning, China.

Abstract

Cytokeratin (CK) 7 is normally expressed in the vast majority of lung adenocarcinoma (ADC). However, on rare occasions, as reported in this paper, CK7 negativity can challenge the diagnosis of pulmonary ADC. Hence, the need to use a combination of 'immunomarkers' such as thyroid transcription factor 1, Napsin A, p40, p63 and CK20.

Keywords: CK20; CK7; Lung Adenocarcinoma; Napsin A; TTF1; cytokeratin; immunochemistry; p40; p63.

Publication types

Case Reports